Merck: inconclusive trial in NSCLC

(CercleFinance.com) - Merck last night provided an update on a phase II trial evaluating MK-7684A, a co-formulation of vibostolimab and pembrolizumab (Keytruda), with or without docetaxel, for the treatment of patients with non-small cell lung cancer (NSCLC) with progressive disease after treatment with immunotherapy and platinum-based doublet chemotherapy.


Results from the open-label arm of this study show that the coformulation failed to meet the primary endpoint of progression-free survival (PFS) and was numerically less effective than docetaxel.

Merck informs the study investigators that patients in this arm of the study should be switched to standard therapy unless otherwise directed by their physician.


Copyright (c) 2023 CercleFinance.com. All rights reserved.